These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 9747424)

  • 41. Tryptophan. Current status and future trends for oral administration.
    Kaufman LD; Philen RM
    Drug Saf; 1993 Feb; 8(2):89-98. PubMed ID: 8452659
    [No Abstract]   [Full Text] [Related]  

  • 42. On-line HPLC-tandem mass spectrometry analysis of contaminants of L-tryptophan associated with the onset of the eosinophilia-myalgia syndrome.
    Williamson BL; Benson LM; Tomlinson AJ; Mayeno AN; Gleich GJ; Naylor S
    Toxicol Lett; 1997 Jul; 92(2):139-48. PubMed ID: 9295237
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Myalgia-eosinophilia syndrome. Tryptophan disease].
    Cabane J
    Rev Prat; 1991 Dec; 41(25):2583-7. PubMed ID: 1803472
    [No Abstract]   [Full Text] [Related]  

  • 44. [Eosinophilia-myalgia syndrome].
    Heuschling C
    Bull Soc Sci Med Grand Duche Luxemb; 1992; 129(2):17-23. PubMed ID: 1340406
    [No Abstract]   [Full Text] [Related]  

  • 45. The eosinophilia myalgia syndrome: to be or not to be.
    Espinoza LR
    Semin Arthritis Rheum; 1997 Jun; 26(6):781-4. PubMed ID: 9213375
    [No Abstract]   [Full Text] [Related]  

  • 46. The eosinophilia-myalgia syndrome revisited.
    Belongia EA; Gleich GJ
    J Rheumatol; 1996 Oct; 23(10):1682-5. PubMed ID: 8895139
    [No Abstract]   [Full Text] [Related]  

  • 47. Synthesis and formation of an EMS correlated contaminant in biotechnologically manufactured L-tryptophan.
    Müller B; Pacholski C; Simat T; Steinhart H
    Adv Exp Med Biol; 1999; 467():481-6. PubMed ID: 10721091
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [A lesson on the purity of pharmaceutical products derived from biotechnology: eosinophilia-myalgia syndrome].
    Boll Chim Farm; 1995; 134(7):394-5. PubMed ID: 7546544
    [No Abstract]   [Full Text] [Related]  

  • 49. Safety of 5-hydroxy-L-tryptophan.
    Das YT; Bagchi M; Bagchi D; Preuss HG
    Toxicol Lett; 2004 Apr; 150(1):111-22. PubMed ID: 15068828
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Synthesis and analysis of contaminants in ems-related tryptophan.
    Steinhart H; van Wickern B; Meyer K; Simat T
    Adv Exp Med Biol; 1996; 398():667-75. PubMed ID: 8906342
    [No Abstract]   [Full Text] [Related]  

  • 51. Effects of tryptophan related compounds on nuclear regulatory control. Possible role in the eosinophilia-myalgia syndrome.
    Sidransky H; Verney E; Latham P; Schwartz A
    Adv Exp Med Biol; 1996; 398():343-50. PubMed ID: 8906287
    [No Abstract]   [Full Text] [Related]  

  • 52. Contaminants in biotechnologically manufactured L-tryptophan.
    Simat T; van Wickern B; Eulitz K; Steinhart EH
    J Chromatogr B Biomed Appl; 1996 Oct; 685(1):41-51. PubMed ID: 8930752
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Eosinophilia myalgia syndrome, toxic oil syndrome].
    Niiyama T; Higuchi I
    Ryoikibetsu Shokogun Shirizu; 2001; (35):358-60. PubMed ID: 11555954
    [No Abstract]   [Full Text] [Related]  

  • 54. A heretofore undisclosed crux of eosinophilia-myalgia syndrome: compromised histamine degradation.
    Smith MJ; Garrett RH
    Inflamm Res; 2005 Nov; 54(11):435-50. PubMed ID: 16307217
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Analytical characterization of peptide contaminants of L-tryptophan.
    Barnhart ER; Maggio VL; Alexander LR; Reilly MC; Gelbaum LT; Turner WE; Hine TK; Needham LL
    Arch Environ Contam Toxicol; 1996 Jan; 30(1):142-8. PubMed ID: 8579384
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Biotechnology. Yellow light on L-tryptophan.
    Aldhous P
    Nature; 1991 Oct; 353(6344):490. PubMed ID: 1922349
    [No Abstract]   [Full Text] [Related]  

  • 57. Over-the-counter melatonin products and contamination.
    Naylor S; Gleich GJ
    Am Fam Physician; 1999 Jan; 59(2):284, 287-8. PubMed ID: 9930125
    [No Abstract]   [Full Text] [Related]  

  • 58. Diagnostic bias in clinical decision making: an example of L-tryptophan and the diagnosis of eosinophilia-myalgia syndrome.
    Wagner KR; Elmore JG; Horwitz RI
    J Rheumatol; 1996 Dec; 23(12):2079-85. PubMed ID: 8970044
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The eosinophilia-myalgia syndrome--guidelines for patient care.
    Hertzman PA; Kaufman LD; Love LA; Mease PJ; Philen RM; Pincus T; Rosenberg NL; Silver R; Varga J; Clauw DJ
    J Rheumatol; 1995 Jan; 22(1):161-3. PubMed ID: 7699664
    [No Abstract]   [Full Text] [Related]  

  • 60. Contaminants in commercial preparations of melatonin.
    Williamson BL; Tomlinson AJ; Naylor S; Gleich GJ
    Mayo Clin Proc; 1997 Nov; 72(11):1094-5. PubMed ID: 9374988
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.